Mereo BioPharma Group plc financial data

Symbol
MREO on Nasdaq
Location
One Cavendish Place, Fourth Floor, London, United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 732 % +23.2%
Debt-to-equity 17.6 % -72%
Return On Equity -75 % +58.9%
Return On Assets -63.7 % -8.04%
Operating Margin -3.92K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 796M shares +2.57%
Entity Public Float 471M USD +228%
Common Stock, Value, Issued 3.13M USD +2.72%
Weighted Average Number of Shares Outstanding, Basic 800M shares +3.87%
Weighted Average Number of Shares Outstanding, Diluted 800M shares +3.87%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 22.4M USD +32.4%
General and Administrative Expense 25.3M USD +7.19%
Operating Income (Loss) -47M USD -19.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -41.6M USD +9.32%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -41.6M USD +8.26%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.7M USD -39.5%
Assets, Current 52.4M USD -39.6%
Property, Plant and Equipment, Net 174K USD -44.8%
Operating Lease, Right-of-Use Asset 378K USD -58.4%
Intangible Assets, Net (Excluding Goodwill) 1.09M USD
Assets 53.6M USD -39.6%
Accounts Payable, Current 879K USD -49.7%
Accrued Liabilities, Current 4.12M USD +16.7%
Liabilities, Current 6.02M USD -57.7%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 652K USD +14.8%
Liabilities 7M USD -56.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10.9M USD +1.75%
Retained Earnings (Accumulated Deficit) -494M USD -8.3%
Stockholders' Equity Attributable to Parent 46.6M USD
Liabilities and Equity 53.6M USD -39.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.33M USD -4.23%
Net Cash Provided by (Used in) Financing Activities 422K USD
Net Cash Provided by (Used in) Investing Activities -320K USD +54.3%
Common Stock, Shares, Issued 795M shares +2.82%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7K USD +75%
Deferred Tax Assets, Valuation Allowance 215M USD +4.21%
Deferred Tax Assets, Gross 215M USD +4.21%
Operating Lease, Liability 397K USD -64.9%
Depreciation 140K USD -17.6%
Payments to Acquire Property, Plant, and Equipment 20K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41.4M USD -18.8%
Lessee, Operating Lease, Liability, to be Paid 410K USD -66.6%
Property, Plant and Equipment, Gross 1.22M USD -4.54%
Operating Lease, Liability, Current 397K USD -46.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 118M USD +6.33%
Operating Lease, Payments 800K USD -0.87%
Additional Paid in Capital 548M USD +2.17%
Amortization of Intangible Assets 106K USD -1.85%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Operating Leases, Future Minimum Payments Due 1.54M USD
Interest Expense 608K USD -54.8%